Last reviewed · How we verify
Oral PF-07220060 (oral-pf-07220060)
Oral PF-07220060, marketed by Pfizer, is positioned in the multiple myeloma segment, a critical area in oncology. The drug's key patent expires in 2028, providing a period of market exclusivity. However, it faces significant competition from other CDK4/6 inhibitors such as Palbociclib, Ribociclib, and Abemaciclib, which are established in treating HR+/HER2- mBC patients.
At a glance
| Generic name | oral-pf-07220060 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Unknown |
| Target | Unknown |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma
Common side effects
Drug interactions
- Warfarin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
- Strong CYP3A inhibitors
- Strong CYP3A inducers
- CYP2C8 inhibitors
- CYP2C8 inducers
- CYP2C19 inhibitors
- CYP2C19 inducers
- CYP2D6 inhibitors
- CYP2D6 inducers
- CYP3A substrates
Key clinical trials
- A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults (PHASE1)
- Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease (PHASE3)
- A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment (PHASE2)
- A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants (PHASE1)
- A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060 (PHASE1)
- A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause (PHASE2)
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral PF-07220060 CI brief — competitive landscape report
- Oral PF-07220060 updates RSS · CI watch RSS
- Pfizer portfolio CI